The HUMEXE project focuses on the challenges faced by people with spinal cord injuries, in particular paraplegics. These people often have limited mobility, which considerably reduces their quality of life. The inability to walk not only affects their physical health, but also their psychological well-being, social interactions and economic opportunities.
During the project, Tecnimusa, an R&D Spanish SME that has improved the current exoskeletons available on the market through the development of the exoskeleton HUMEXE. This new exoskeleton follows an entirely different approach for the movements control strategy. HUMEXE, as contrast to the rest of exoskeletons, bases the movement control of the lower limbs on the movement of the upper limbs of the individual, thus providing the user the full control of his movements, instead of being a control unit in control of the movements and their trajectories.
This new approach allows the user to control the lower limbs’ movements without the aid of crutches or the supervision of another person, and these movements will be performed more accurately than competitors,’ thanks to the increase of freedom degrees of the exoskeleton (13, in contrast of a maximum of 10 and an average of 4 in other competitors). Besides dramatically reduces the computing requirements of the control unit, resulting in a simpler device, fail-safer and cheaper, easing the access to the exoskeleton to the general public.
In addition, to improve the usability and effectiveness of HUMEXE, Tecnimusa has developed a comprehensive learning protocol, which is a guide structured in different steps that support patients in acclimatising to the process of walking with the exoskeleton, and a learning vehicle that has been designed to support patients while they become familiar with the exoskeleton and prevent them from falling.
Since the beginning of the project, a total of 9 patients participated in two distinct rounds of clinical trials, providing invaluable insights into the effectiveness of our learning protocol and the HUMEXE exoskeleton. Throughout these trials, the results were very promising. Patients demonstrated significant progress in their ability to use the HUMEXE exoskeleton, with many showing substantial improvements in mobility and autonomy.
Finally, efforts have been made to approach HUMEXE to the market, such as steps to protect intellectual property, the development of an Investors Ready Business Plan and progress on CE marking of the device.